Clodronate for Treating Tumor Induced Hypercalcaemia
Author Information
Author(s): Shah S, Hardy J, Rees E, Ling J, Gwilliam B, Davis C, Broadley K, A'Hern R
Primary Institution: The Royal Marsden NHS Trust
Hypothesis
Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia?
Conclusion
Clodronate is a safe and effective treatment for tumor induced hypercalcaemia, but the study did not confirm a dose response relationship.
Supporting Evidence
- The overall response rate was 49.3%.
- There was no significant difference in response rates across all dose groups.
- Patients were well matched for age, sex, and tumor type.
Takeaway
This study looked at how different doses of clodronate help people with high calcium levels due to cancer, and found that lower doses work just as well as higher ones.
Methodology
A partially randomised, non-blinded study comparing four doses of intravenous clodronate in patients with tumor induced hypercalcaemia.
Limitations
The study had a small sample size for some groups and excluded patients with haematological malignancies.
Participant Demographics
Patients were aged over 18 years with non-haematological malignancies.
Statistical Information
P-Value
P=0.14
Confidence Interval
95% CI: 36.8–61.8
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website